MAZELSKY JONATHAN JAY sold $17.7M of IDXX
MAZELSKY JONATHAN JAY (Executive Chair of the Board) sold 25,140 shares of IDEXX LABORATORIES INC /DE (IDXX) at an average of $703.19 ($698.26–$711.95, $17.68M total) across 13 trades on 2026-11-04.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public report of this transaction, making it a primary source of new information.
Market read
Insider sell of $17.7 M may trigger short interest and price dip in IDEXX.
What to watch
No 10b5‑1 plan; the timing may be unrelated to company fundamentals.
Background
Form 4 filings disclose insider transactions; large sales by executives often attract trader attention.
Ticker impact
Executive Chair Jonathan Jay Mazelsky sold 25,140 shares of IDEXX Laboratories for $17.7 M, reducing his stake to 83,803 shares.
likely downward pressure as the market prices in the insider sell.
A $17.7 M open‑market sale by a top insider is material and new, suggesting potential concerns.
Market effects
May prompt scrutiny of other biotech insiders' holdings.
Limited to U.S. biotech sector.
Low; primarily affects IDEXX shareholders.
Counterpoint
The sale could be a routine portfolio rebalancing, not a negative signal.
Key entities
- personJonathan Jay Mazelsky
Executive Chair of IDEXX Laboratories


